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The knowledge of the status of axillary lymph nodes (LN) of patients with breast cancer is a fundamental prerequisite in the
therapeutic decision. In the present work, we evaluated the impact of fine-needle aspiration cytology (FNAC) of ultrasonographically
(US) selected axillary LN in the diagnosis of LN metastases and subsequently in the treatment of patients with breast cancer. Axillary
US was performed in 298 patients with diagnosed breast cancer (267 invasive carcinomas and 31 ductal carcinoma in situ DCIS), and
in 95 patients it was followed by FNAC of US suspicious LN. Smears were examined by routine cytological staining. Cases of
uncertain diagnosis were stained in immunocytochemistry (ICC) with a combination of anticytokeratin and anti-HMFG2 antibodies.
Eighty-five FNAC were informative (49 LN were positive for metastases, 36 were negative). In 49 of 267 patients with invasive breast
carcinoma (18%), a preoperative diagnosis of metastatic LN in the axilla could be confirmed. These patients could proceed directly to
axillary dissection. In addition, US-guided FNAC presurgically scored 49 out of 88 (55%) metastatic LN. Of all others, with
nonsuspicious LN on US (203 cases including 31 DCIS), in which no FNAC examination was performed, 28 invasive carcinomas
(16%) turned out to be LN positive on histological examination. Based on these data, US examination should be performed in all
patients with breast cancer adding ICC-supported FNAC only on US-suspect LN. This presurgical protocol is reliable for screening
patients with LN metastases that should proceed directly to axillary dissection or adjuvant chemotherapy, thus avoiding sentinel
lymph node biopsy.
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Management of breast cancer patients is much improved since the
introduction of multidisciplinary treatment centres. The relation
between diagnosis and therapy is gradually becoming closer as
ever more sophisticated diagnostic tools and new therapeutic
strategies become available (Greco et al, 1998; Cady, 2000). For
example, neoadjuvant chemotherapy can dramatically downstage
both the primary tumour and the axilla, making many patients
good candidates for breast-conserving surgical techniques (Sin-
gletary, 2001). However, at the same time, this poses new
questions, such as the adequacy of diagnostic preoperative staging
of the axillary lymph nodes (LN) in order to adopt specific
therapeutic decisions. Besides clinical examination, different
sophisticated imaging techniques have been proposed as alter-
native methods in the staging of axillary LN in breast cancer
(Kvistad et al, 2000; Shimizu et al, 2000; Nishiyama et al, 2001).
However, none of these procedures has been successful enough to
replace histological examination. The introduction of the sentinel
lymph node biopsy (SLNB) has partly solved the problem. In fact,
the low rate of skip metastases in breast cancer gives to the SLN the
role of reliable indicator of the status of the axilla, thereby avoiding
nodal dissection, a surgical procedure that exposes patients to
morbidity not justified by the benefit/risk ratio (Gervasoni et al,
2000). However, the main objections to SLNB are that the
technique per se is quite complex and that the adequacy of the
biopsy relies too much on the skill and experience of the surgeon
(ADASP, 2001). In addition, the method used to perform
histological examination of the SLN is debated and varies
depending on the guidelines followed by the pathologist (ADASP,
2001; Kane et al, 2001; Turner et al, 2001; Veronesi et al, 2001).
To take the problem a step further, the ideal approach would be
to employ a simple preoperative procedure that would allow
selection of those patients who should directly undergo axillary
dissection, sparing them SLNB. There are very few reports of
image-guided LN fine-needle aspiration cytology (FNAC) as a
means of improving presurgical staging of the axilla in breast
cancer patients (Bonnema et al, 1997; Verbanck et al, 1997; de
Kanter et al, 1999).
The aim of the present study was to evaluate the possibility of
introducing ultrasonographic (US) examination of axillary LN in
association with FNAC as a useful diagnostic tool in the
presurgical management of patients with breast cancer.
MATERIALS AND METHODS
Case series
In 2000, a total of 298 patients with breast carcinomas were
operated in the Breast Unit of the San Giovanni Hospital (Torino,
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yItaly). All these patients underwent presurgical FNAC or core
biopsy of the breast lesions. In both procedures, sample adequacy
was immediately evaluated by rapid haematoxylin–eosin (H&E)
staining of one smear. It was also possible to assess the adequacy
of core biopsies by smearing the tissue fragments on a slide that
was then fixed in methanol and immediately stained. Using this
method, the number of core samples per case ranged from 1 to 3.
In addition, before surgery all these 298 patients underwent
clinical and US examination of the ipsilateral axillary LN carried
out by the radiologist using a linear array transducer, small parts
probe 10MHz, Hitachi ‘Astro’ (Hitachi Medical Systems, Tarry-
town, BY, USA). The US features considered as suspect were two-
dimensional enlargement giving a rounded appearance to the LN,
echopoor central hilus and eccentricity of the nodal cortex. Ninety-
five patients with LN presenting at least one of the previous
features were considered suspect for metastases and therefore
investigated by US-guided FNAC. When more than one LN
suspected for metastasis was detected, only the largest or more
suspicious one was aspirated, but when this turned out to be
negative, the aspiration was performed on the other US-suspect
LN. Several free-hand passes were made into each suspect LN
using a 22-gauge needle. The number of US-recognised axillary LN
was recorded and compared with the number of LN at axillary
dissection, when performed.
Smear preparation
The lymph node aspirated material was completely smeared onto
two to three slides, immediately fixed in methanol and stained with
rapid H&E. In order to recognise sporadic neoplastic cells,
undetectable by routine staining, selected smears that were
negative for cancer cells by H&E were evaluated by immuno-
cytochemistry (ICC) with a locally produced cocktail (1:1
solution) of mouse monoclonal antibodies against two epithelial
antigens, anticytokeratin (clone kl1, Immunotech, Marseille,
France; dil. 1:50) and antiepithelial membrane antigen (clone
HMFG-2, kindly supplied by J. Taylor Papadimitriou, London, UK;
dil. 1:30). In brief, the slides were demounted, rehydrated in
distilled H2O, rinsed in PBS and incubated for 30min at room
temperature with the cocktail of primary antibodies. The slides
were then incubated for 20min with a secondary biotinylated
antibody and with streptavidin–peroxidase conjugate (1:50,
StrAviGen MultiLink
s Kit, BioGenex, S.Ramon, CA, USA) for
another 20min at room temperature. Finally, 30-3-diaminobenzi-
dine (DAB) chromogen solution (LiquidDAB Substrate Pack,
BioGenex) was used to reveal the reactions.
The cytological diagnoses of the aspirated LN were compared
with the histological diagnosis either of axillary LN dissection or of
SLNB. Sensitivity, specificity and positive and negative predictive
values of US-guided FNAC were calculated.
Sentinel lymphnode examination
Sentinel lymph node were longitudinally bisected through the
hilus, with further sectioning if the halves were thicker than 2mm
(Turner et al, 2001). The microscopic examination was assessed
first on four sections stained with H&E and then negative LN were
evaluated at two additional levels with ICC using the same cocktail
of antibodies used for cytology.
RESULTS
Of the 298 breast cancer operated, 31 (10.5%) were in situ and 267
(89.5%) were invasive carcinomas. In 75 patients with invasive
carcinomas, the SLNB was feasible and successfully performed; the
other patients underwent axillary dissection. Lymph nodes
metastases were present in 88 cases (33%) (pN+). Only 16 out of
75 (21.3%) SLN were affected by metastases (Figure 1). All patients
underwent US examination before surgery. The number of US-
recognised LN was in general lower than the number of LN at
axillary dissection.
In 95 patients US of axillary LN was followed by FNAC. No
clinical complications associated to FNAC were observed in any
patient. Forty-nine samples were positive and 36 were negative for
carcinoma cells and 10 samples were noninformative for diagnosis
(Figure 1 and Table 1). Comparison of the cytological results with
the histological diagnosis provided by axillary dissection or by
SLNB showed that FNAC was endowed with high sensitivity and
absolute specificity as all 49 positive cases were true positives. In
nine of these cases the cytological diagnosis of metastases was
supported by cytokeratin and HMFG-2 immunostaining that
outlined scattered cancer cells (Figure 2C, D) (Table 2). The
immunostaining resulted particularly useful in seven cases where
the primary tumour was an invasive lobular carcinoma. In nine
patients selected for adjuvant chemotherapy, US-guided FNAC
revealed the presence of LN metastases. Six of the 36 (16%)
negative cytological diagnoses were false negatives since LN
metastases were found by histology (Figure 1 and Table 2). In
one case, the lymph node was affected by a micrometastasis
(diameter p2mm), in two cases, the lymph node metastasis was
smaller than 4mm and in three cases the metastases were smaller
than 0.9cm but invaded the LN capsule. In these false negative
cases, ICC was also negative, suggesting that the FNAC sample was
probably obtained either in a nonmetastatic LN area or in a
reactive LN. Overall, the results indicate that ICC increases the
sensitivity of routine cytological diagnosis (Table 2).
In 10 cases, the cellularity of the FNAC samples was too poor to
consent diagnosis (Figure 1). Despite this, the FNAC procedure
was not repeated because the position of the LN was too difficult to
be reached or the node was too small. In five of these cases,
histology showed the presence of metastatic LN, none larger than
5mm (Table 2).
DISCUSSION
In the present study, we demonstrate that US-guided FNAC of
axillary LN in breast cancer patients can reliably predict the
presence of metastases and therefore refer the patients to the
appropriate surgical treatment, avoiding the SLNB. In fact, in our
series, US-guided FNAC presurgically screened 18% of invasive
breast carcinoma operated in the same year and scored 49 out of
88 (55%) of the metastatic LN.
Since the early 1980s, US examination has been proposed by
many authors as one of the most successful procedures for
evaluating the status of the axilla in breast cancer patients before
surgery (Bruneton et al, 1986; Pamilo et al, 1989; Mustonen et al,
1990; Yang et al, 1996; Strauss et al, 1998;). Sonography can easily
explore the different nodal chains and, when LN are found, specific
signs may be searched to evaluate the presence of metastases (Feu
et al, 1997; Rizzatto, 2001). We here reported a 16% false negative
rate by US alone, since 28 out of 172 of US-nonsuspect LN were
positive at histology. However, a great improvement of the
diagnostic accuracy emerged when US examination was combined
with FNAC of LN suspect to be metastatic, as demonstrated by the
few available reports on the subject (Bonnema et al, 1997;
Verbanck et al, 1997; de Kanter et al, 1999, 2000). In fact, in our
study and in previous ones that used a similar approach, the
cytological diagnosis of metastases reached 100% specificity. On
the other hand, Bonnema et al (1997) reported 80% sensitivity and
a 76% negative predictive value of the cytological method. In the
present work, we observed an increase in both sensitivity (89%)
and negative predictive value (84%), which has to be related to the
additional use of ICC. The use of a cocktail of antiepithelial
membrane antigen and antipancytokeratin antibodies for identify-
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ying scattered epithelial cancer cells has been proposed recently in
bone marrow smears (Gebauer et al, 2001). The possibility of using
the same smears obtained for routine H&E staining for additional
ICC analyses with the cocktail of antibodies recognising different
antigens is an interesting approach, which reduces further
sampling of the LN, and limits potential diagnostic pitfalls. In
fact, cytokeratin-positive interstitial reticulum cells present in
normal or reactive LN may complicate interpretation of the results
(Linden and Zarbo, 2001) and, on the other hand, the epithelial
membrane antigen may enhance both sensitivity and specificity of
the procedure, particularly for metastases of invasive lobular
breast cancer. In the present series, in seven out of nine metastatic
cases diagnosed by ICC, the primary tumour was an invasive
lobular carcinoma with scattered neoplastic cells dispersed among
lymphocytes and clearly outlined only by ICC.
In a recent multicentre study, de Kanter et al (1999)
demonstrated that, using US combined with FNAC in patients
without palpable axillary nodes, SLNB could be avoided in 17% of
cases since cytology had already diagnosed axillary metastases.
Similarly, in our experience, 18% of metastatic invasive carcino-
mas were already diagnosed using US-guided FNAC, which
presurgically scored 49 out of 88 (55%) of the metastatic LN.
In addition, the method could be particularly valuable in cases
of extensive metastatic involvement, which is the cause of false
negative SLNB procedures (Dequanter et al, 2001). In fact, when a
LN is completely replaced by the tumour, there is poor uptake of
radioactivity. In our series, the whole group of pN2 LN were
positive by cytological examination.
The requirement of neoadjuvant chemotherapy appears to be an
additional indication for US-guided FNAC LN examination.
Systemic chemotherapy has been broadened to include all invasive
tumours larger than 1 cm regardless of axillary status (Fisher et al,
1998). Nevertheless, to establish the metastatic status of LN can be
useful for evaluating the response to chemotherapy and the
prognostic work-up of patients who are not surgical candidates. In
the present series, nine of the patients enrolled by the oncologist
FNAC
203 US-nonsuspect LN
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US-Axillary LN
SLNB
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5
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8
5
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LN+
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2
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4
2
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49 FNAC positive
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10 FNAC not informative
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breast cancer
FNA and/or
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267 invasive 
carcinomas
Surgery
A.D. =axillary dissection; LN+=number of cases with lymph node metastases.
31 in situ carcinomas: 
No A.D.
No SLNB
172 invasive carcinomas
Figure 1 Diagnostic protocol of 298 patients with breast cancer.
Table 1 Correlation of tumour size with histological and FNAC diagnosis of axillary lymph node status in 95 patients
Tumour size (cm) FNAC– N– FNAC– N+ FNAC+ N+ FNAC na N– FNAC na N+ Total
o0.5 4 0 0 0 0 4
0.5–1 13 0 2 0 3 18
1–2 8 4 18 5 1 36
>2 5 2 29 0 1 37
FNAC =cytologically negative, FNAC+=cytologically positive, FNAC na=not adequate; N =histologically negative, N+=histologically positive
US-guided FNAC of axillary lymph nodes
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using the guided FNAC procedure.
Finally, in a quality control programme, the evaluation of the
standard goal that range from 32 to 40% of metastases in the SLNB
(de Kanter et al, 2000; Rahusen et al, 2001; Veronesi
et al, 2001) has to be re-evaluated taking into account that
most of the metastatic LN can be already diagnosed with US-guided
FNAC. In the present series, the selection of cases markedly
reduces the percentage of metastatic SLNB with respect to the
values accepted in the literature and, at the same time, increases
the number of axillary dissection as first-choice treatment. Thus,
US-guided FNAC of axillary LN could generate cost savings to the
health care system by reducing the added cost incurred by
subsequent axillary dissection for the patients who show metastatic
SLN.
In conclusion, because of its low cost and high specificity, we pro-
pose that examination by US of the axilla in patients with diagnosed
breast cancer should be performed any time before surgery. FNAC of
selected LN should be added to the diagnostic protocol, in order to
directly schedule patients with a cytological diagnosis of LN
metastases to the appropriate treatment, avoiding the SLNB.
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Figure 2 (A) Hematoxylin & Eosin stained smear of a US-guided FNAC in a selected axillary lymph node in breast cancer ( 200 original magnification)
(inset). (B) In a background of lymphocytes and red cells one large cell with hyperchromatic nucleus is evident (1000  original magnification. (C), (D) The
cocktail of antipancytokeratin and antiepithelial membrane antigen antibodies outlines numerous noncohesive metastatic cells of a lobular infiltrating
carcinomas scattered among the lymphocytes ( 200 original magnification).
Table 2 Impact of ICC on FNAC diagnosis of LN metastases
FNAC positive (49 cases) FNAC negative (36 cases) FNAC not adequate (10 cases)
LIMPH node histology ICC H&E ICC H&E H&E Total
No metastases 0 0 21 9 5 35
Metastases of 0.2–1cm 8 33 6 0 3 52
Metastases of 1–2cm 1 7 0 0 0 8
Predictive values of FNAC: Sensitivity=89%; specificity=100%; positive predictive value=100%; negative predictive value=82.3%.
US-guided FNAC of axillary lymph nodes
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